Hypoparathyroidism Treatment Market Snapshot (2023 to 2033)
The global hypoparathyroidism treatment market was valued at US$ 777.4 million as of 2022 and is likely to reach US$ 841.9 million in 2023. During the 2023 to 2033 forecast period, the market is expected to incline at a CAGR of 7.7%, and is expected to total US$ 1,767.4 million by the end of the said period of assessment.
Parathyroid hormone (PTH) plays a pivotal role in maintaining the optimum level of calcium, phosphate, and calcitriol (active Vitamin D) in the blood and bones. Hypoparathyroidism is an uncommon endocrine disorder that develops due to low production or absence of parathyroid hormone.
Globally, hypoparathyroidism affects approximately 200, 000 people, out of which most cases are associated with accidental damage or removal of the parathyroid gland during thyroid surgery. Other cases are associated with autoimmune, hereditary, and idiopathic issues. The current standard treatment involves the use of calcium and vitamin D analogues (Vitamin D2 & Vitamin D3).
On the other hand, hormonal therapy is also gaining attention, where the primary treatment has found success in cases of severe hypoparathyroidism. The side effects include potential risks associated with developing osteosarcoma has limited adoption rates. Manufacturers in the market are focusing on investing significantly in the development of safe, and effective hormonal therapies in long-term strategies.
Attributes
Details
Hypoparathyroidism Treatment Market Value (2022)
US$ 777.4 million
Hypoparathyroidism Treatment Market Value (2023)
US$ 841.9 million
Hypoparathyroidism Treatment Market Expected Value (2033)
US$ 1,767.4 million
Hypoparathyroidism Treatment Market Projected CAGR (2023 to 2033)
7.7%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
How Does the Future Outlook for Hypoparathyroidism Treatment Market Compare to Historical Data?
Between 2018 and 2022, the demand for calcium supplements for treating hypoparathyroidism dominated the global market mainly owing to cost and efficacy benefits over hormonal therapies and other drugs. Subsequently, rising research and development activities supported market growth.
NATPARA (Takeda), and Rocaltrol (Roche) are some of the commonly prescribed drugs to treat moderate to severe hypoparathyroidism. Issues of product recall and the resultant mismanagement of treatments have led to hospitalizations in severe cases. Manufacturers such as Ascendis Pharma A/S, EnteraBio Ltd, ProLynx, Inc., and Extend Biosciences, Inc. have hormonal therapies in the pipeline which have delivered superior patient outcomes.
The market is expected to witness an increase in patient screening for several thyroid conditions owing to growing patient awareness. The approval and designation of hypothyroidism drugs as orphan products by the United States FDA and the European Commission (EC), coupled with the untapped patient population is expected to have a positive impetus on market growth.
The emergence of personalized medicines, the rapid rise in demand for biologics for hypothyroidism, and consolidation activities by market players will create significant opportunities for the expansion of the hypothyroidism treatment market size over the forecast period, which is projected to expand at a CAGR of 7.7% through 2033.
How are Changes in Reimbursement Policies Fueling Market Growth?
Government Initiatives to Propel Market Growth
Government support in terms of receiving an orphan drug designation from regulatory bodies such as the United States FDA and European Commission (EC) and financial and tax incentive factors are expected to result in a high return on investment for companies developing novel drugs for treating hypoparathyroidism.
The United States FDA’s orphan drug status is given to biologics affecting fewer than 200,000 people in the United States alone with the benefits of various incentives including tax incentives for qualified clinical trials and market exclusiveness on receiving regulatory approval.
For hypoparathyroidism, NATPARA is the only drug issued with a black box warning, which was notified by United States FDA, in January 2015, and currently has exclusivity until 2022. Also, the treatment is covered by several insurance companies and co-pay policies. Such initiatives are expected to boost the production of novel drugs, which is expected to positively influence the growth of the market shortly.
Find your sweet spots for generating winning opportunities in this market.
Why are Labelling Restrictions on NATPARA Limiting Market Growth?
Side Effects Owing to the Usage of NATPARA to Restrict the Market Expansion
Currently, NATPARA is the only available drug to treat hypoparathyroidism. Because of its side effects including a potential risk of osteosarcoma, high blood calcium levels, and reduced sense of touch or pain sensation in joints, which could result in hospitalization. The drug is only made available through NAPTARA Risk Evaluation and Mitigation Strategy (REMS) Programs.
Hence, in most of the cases, oral medications are considered as standard treatment for hypoparathyroidism. This limits the adoption of available hormonal therapy. Further, long-term beneficial drug usage symptoms have still not been demonstrated across clinical trials, which might limit the adoption of therapy in patients given the high price of the injection. Drug literature review 2018 states that therapy with rhPTH (1-84) is a long-term management option, where more long-term efficacy and safety data are needed in humans. EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for NATPARA instead of these side effects. Thus, labeling restrictions are expected to hold back the penetration of NATPARA in the major global markets, thereby hampering the overall growth of the market.
How are Small Molecule Biologics Creating Growth Opportunities?
The Development of Biologics is Anticipated to Drive Market Growth
The hypoparathyroidism treatment market is shifting towards the demand for biologics over conventional drug alternatives. The efficacy of biologics and their ability to mimic natural body hormones is greater as compared to small molecule options in conventional therapy. This benefit is an essential influencing factor driving the demand for biologics.
Bologics promote the conversion of vitamin D into active forms, which increases the absorption of oral calcium supplements, resulting in synergies with conventional calcium in supplement therapy. Considering the aforementioned factors, the emergence of biologics is expected to offer lucrative opportunities for the growth of the hypothyroidism treatment market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Comparative Analysis of the Adjacent Markets
Hypoparathyroidism Treatment Tools Market:
Differentiating Aspects
Hypoparathyroidism Treatment Tools Market
CAGR (2023 to 2033)
7.7%
Market Valuation in 2023
US$ 841.9 million
Projected Market Value in 2033
US$ 1,767.4 million
Growth Factors
The market is expected to witness an increase in patient screening for several thyroid conditions owing to growing patient awareness.
Opportunities
The emergence of personalized medicines, the rapid rise in demand for biologics for hypothyroidism, and consolidation activities by market players will create significant opportunities for the expansion of the hypothyroidism treatment market
Key Trends
The emergence of personalized medicines and consolidation activities by market players.
Hypocalcaemia Treatment Market:
Differentiating Aspects
Hypocalcaemia Treatment Market
CAGR (2023 to 2033)
5.6%
Market Valuation in 2023
US$ 3.5 billion
Projected Market Value in 2033
US$ 6 billion
Growth Factors
The increased prevalence of hypocalcemia, rising knowledge about the advantages of early detection and treatment, and increasing preferences for preventative therapies are driving market expansion.
Opportunities
Due to the growing number of clinics performing evaluations for patients with symptoms comparable to osteoporosis or bone fractures, the clinic is likely to encounter substantial market opportunities throughout the projection period.
Key Trends
Rising consciousness regarding a healthy lifestyle that includes regular exercise and nutritious foods
Thyroid Gland Disorder Treatment Market:
Differentiating Aspects
Thyroid Gland Disorder Treatment Market
CAGR (2023 to 2033)
3.4%
Market Valuation in 2023
2.44 billion
Projected Market Value in 2033
3.41 billion
Growth Factors
The primary drivers driving market expansion include a spike in the prevalence of thyroid gland problems, an increase in illness awareness programs, particularly in emerging countries, and the development of potent combination pharmacological regimens to treat thyroid gland disorder.
Opportunities
An rise in collaboration partnerships between private and public organizations to raise thyroid management knowledge among medical specialists and patients.
Key Trends
Pharmaceutical businesses are taking steps to assist initiatives to promote awareness or to employ promotional techniques to raise consciousness.
Country-wise Insights
What are the Prospects of Adoption for Hypoparathyroidism Treatments in the United States?
United States to Take Over the North American Market
NATPARA (parathyroid hormone), is a recombinant hormonal therapy approved in the United States for the treatment of hypoparathyroidism. It is prescribed to patients who do not show positive results from standard therapies including calcium supplements and vitamin D.
In September 2019, Takeda Pharmaceutical Company Limited announced the recall for all its doses of NATPARA injections in the United States This recall was attributed to the presence of small rubber particles in solution samples, which originated from the rubber septum of the NATPARA cartridge.
This recall of injectable PTH in the United States has created distress among the patients and had a significant impact on treatment cycles. Around 2,700 patients have been affected by the shortage. Patients who are currently being treated with the therapy, have been pushed back to oral medications including calcium supplements and activated vitamin D to control their symptoms.
This transition has created a negative impact on disease management, leading some patients to hospitalization because of severe hypocalcemia. Further, manufacturers anticipate that the PTH injectable will require another year to return to the market. United State has emerged as a leading market, held over 37.7% of the total demand registered in 2022.
Why is Germany leading the Europe Hypoparathyroidism Treatment Market?
High Incidence of Parathyroid Diseases in Germany to Propel The Market Growth
Factors such as rising occurrences of parathyroid diseases, rising government initiatives, increasing medical care expenditure, better regulatory scenarios, and rising reimbursement policies and funding are persistently aiding the expansion of the hypoparathyroidism treatment market in Germany. As indicated by the information proposed by Eurostat, it is seen that among the EU Member States, the largest share of medical care expenditure was recorded in Germany in 2019.
Further, growing approvals and orphan drug designation from the European Commission (EC), increasing candidates in clinical trials for the development of hormonal therapy, presence of pharmaceutical players, which leads to better availability of products across the continent, are some of the factors that are responsible for making Germany, one of the largest market for hypoparathyroidism in Europe. Germany held a market share of 8.2% in 2022.
How Are Government Initiatives Boosting Hypoparathyroidism Treatment Market in India?
Adoption of Sophisticated Technology to Raise The Market Demand in India
Implementation of government programs aimed at offering affordable and quality healthcare is expected to complement the growth of India's biopharma industry, in turn creating opportunities for the hypoparathyroidism treatment market. Increasing adoption of technologically advanced treatment and rising awareness among people in India is fuelling the demand for hypoparathyroidism treatment.
India is also considered one of the top destinations of thyroid related disorders in the world, increasing the need for the Hypoparathyroidism Treatment market in the region. Increasing patient pool due to the rise in population, emergence of new diseases, and lifestyle changes are also boosting demand for biopharmaceuticals, which is expected to provide a high opportunity for providers of hypoparathyroidism treatment. The market in the India is poised to grow at a CAGR of 8.6% over the upcoming decades.
Category-wise Insights
How are Calcium Supplements Contributing to Market Revenue?
Calcium Supplements Segment to Grow Owing to The Lowered Side Effects
Hypoparathyroidism is characterized by low parathyroid hormone secretions which results in low calcium levels in the body. Calcium supplements are preferred as the first line of treatment by doctors to normalize the deficiency.
These supplements show a reduced risk of side effects as compared to hormonal therapy. The recent United States recall of the NATPARA compelled patients to opt for oral medication such as calcium supplements to treat the symptoms. These factors will drive demand for calcium supplements, accounting for the largest share of the global market. The calcium supplements segment accounted for a market revenue of 38.29% in 2022.
Which is the Preferred Route of Administration for Hypoparathyroidism Treatment?
Oral Segment to Dominate the Industry
The oral segment by route of administration, held the highest market share due to rising product launches and the presence of a solid pipeline. Various factors like a rapid delivery of drugs, high efficacy, and a higher rate of bioavailability are projected to impel the oral segment development. For drugs having medium to high oral availability, the oral route of administration is effective.
Oral treatments limit the utilization of central lines for intravenous drug administration and accordingly, decrease the danger of complications related to it and also a hospital stay. The advancement of promising new medications and potential clinical pipeline applicants are a portion of the major factors expected to boost segment development. The oral segment held a market revenue of 66.67% in 2022.
What is the share of Hospital & Retail Sales in the global Hypoparathyroidism Market?
Hospital Segment is to Expand Owing to The Rapid Delivery of Medications
The hospital and retail sales are expected to show the maximum share in the market among all distribution channels due to the increasing number of facilities and easy accessibility to patients. Also, the quick delivery of medicines is one of the major factors driving the market growth during the forecast period.
As there are rising numbers of cases of hypoparathyroidism, there is increasing demand for faster accessibility and availability of medicine to treat the disorder as rapidly as possible. Thus, hospitals and retail providers can provide medicines to patients at a faster rate which in turn increases the hypoparathyroidism treatment market.
Competitive Landscape
The global hypoparathyroidism treatment market is dominated by top manufacturers -Takeda Pharmaceutical Company Limited., Entera Bio Ltd., F. Hoffmann-La Roche Ltd, Amgen Inc., and Ascendis Pharma A/S Manufacturers are focusing on enhancing their global and regional presence through acquisitions and collaboration strategies.
In January 2019, Takeda Pharmaceutical Company acquired Shire plc. With this aquisition, Takeda strengthened its geographic presence in the United States, which is one of the key markets for biopharmaceuticals. Also, the acquisition of Shire has strengthened Takeda’s product portfolio and provided it with a leading position in GI, neuroscience, rare diseases, oncology, and PDT.
Ascendis Pharma established VISEN Pharmaceuticals, in November 2018, and collaborated to develop, manufacture, and commercialize the company’s TransCon Endocrinology Rare disease therapies in Greater China. This includes mainland China, Hong Kong, Macau, and Taiwan. Such collaborations are anticipated to expand TransCon PTH’s reach in Asian economies.
In March 2021, BridgeBio Pharma announced positive outcomes from the 2nd stage trial of its new drug Encaleret. As a part of hypoparathyroidism treatments, the drug has shown effectiveness among patients with autosomal dominant hypocalcemia type 1.
In May 2023, Amolyt Pharma disclosed an oral presentation at the 25th European Congress of Endocrinology (ECE) 2023. The presentation emphasizes the potential benefits of eneboparatide as a therapy for hypoparathyroidism, a condition in which numerous people have or are susceptible for acquiring osteopenia and osteoporosis.
The Food and Drug Administration (FDA) approved for Priority Assessment a new drug application (NDA) for TransConTM PTH (palopegteriparatide) in adults diagnosed with hypoparathyroidism in November 2022.
Scope of Report
Attribute
Details
Forecast Period
2023 to 2033
Historical Data Available for
2018 to 2022
Hypoparathyroidism Treatment Market Value (2023)
US$ 841.9 million
Hypoparathyroidism Treatment Market Expected Value (2033)
US$ 1,767.4 million
Market Analysis
US$ million for Value
Key Regions Covered
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Key Countries Covered
United States
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Segments Covered
Product Type
Route of Administration
Distribution Channel
Region
Key Companies Profiled
Takeda Pharmaceutical Company Limited.
Entera Bio Ltd.
Amgen Inc.
Ascendis Pharma A/S
F. Hoffmann-La Roche Ltd
ProLynx, Inc.
Extend Biosciences, Inc.
BionPharma Inc.
Teva Pharmaceuticals Ltd.
Customization & Pricing
Available upon Request
Hypoparathyroidism Treatment Market Segmentation
By Product Type:
Parathyroid Hormone
Natpara
Others
Vitamin D Analogue
Vitamin D2
Vitamin D3
Calcium Supplements
By Route of Administration:
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Sales
By Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Frequently Asked Questions
What is the expected valuation of the global hypoparathyroidism treatment market in 2023?
The global hypoparathyroidism treatment market is estimated to be valued at US$ 841.9 million in 2023.
What was the growth rate of the global hypoparathyroidism treatment market from 2017 to 2022?
The global market for hypoparathyroidism treatment rose at a CAGR of 5.1% from 2017 to 2022
What is the growth outlook for the global hypoparathyroidism treatment market until 2033?
The global hypoparathyroidism treatment market is expected to progress at a CAGR of 7.7% from 2023 to 2033
What is the CAGR of the market for hypoparathyroidism treatment in India?
The market in India is projected to rise at a CAGR of 8.6% over the upcoming decade
What is the expected valuation of the global hypoparathyroidism treatment market in 2033?
The global hypoparathyroidism treatment market is predicted to account for US$ 1,767.4 million by 2033.
Which is the most lucrative market for hypoparathyroidism treatment?
United States has emerged as a leading market, holding over 37.7% of the total demand registered in 2022.
What is the CAGR of the hypoparathyroidism treatment market in China?
The market in China is projected to rise at a CAGR of 7.9% over the upcoming decade
What is the market share of calcium supplements treatment?
The calcium supplements segment accounted for a market revenue of 38.29% in 2022.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
5.3.1. Parathyroid Hormone
5.3.1.1. Natpara
5.3.1.2. Others
5.3.2. Vitamin D Analogue
5.3.2.1. Vitamin D2
5.3.2.2. Vitamin D3
5.3.3. Calcium Supplements
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Parenteral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Sales
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Product Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Product Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Product Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Product Type
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product Type
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Product Type
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Product Type
15.2.3. By Route of Administration
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product Type
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Product Type
16.1.2.2. By Route of Administration
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Product Type
16.2.2.2. By Route of Administration
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Product Type
16.3.2.2. By Route of Administration
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Product Type
16.4.2.2. By Route of Administration
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Product Type
16.5.2.2. By Route of Administration
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Product Type
16.6.2.2. By Route of Administration
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Product Type
16.7.2.2. By Route of Administration
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Product Type
16.8.2.2. By Route of Administration
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Product Type
16.9.2.2. By Route of Administration
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Product Type
16.10.2.2. By Route of Administration
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Product Type
16.11.2.2. By Route of Administration
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Product Type
16.12.2.2. By Route of Administration
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Product Type
16.13.2.2. By Route of Administration
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Product Type
16.14.2.2. By Route of Administration
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Product Type
16.15.2.2. By Route of Administration
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Product Type
16.16.2.2. By Route of Administration
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Product Type
16.17.2.2. By Route of Administration
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Product Type
16.18.2.2. By Route of Administration
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Product Type
16.19.2.2. By Route of Administration
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Product Type
16.20.2.2. By Route of Administration
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Product Type
16.21.2.2. By Route of Administration
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Product Type
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Takeda Pharmaceutical Company Limited.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Entera Bio Ltd.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Amgen Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Ascendis Pharma A/S
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. F. Hoffmann-La Roche Ltd
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. ProLynx, Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Extend Biosciences, Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. BionPharma Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Sun Pharmaceutical Industries Ltd.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Teva Pharmaceuticals Ltd.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Product Type, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 17: Global Market Attractiveness by Product Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 37: North America Market Attractiveness by Product Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Product Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 77: Europe Market Attractiveness by Product Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 97: South Asia Market Attractiveness by Product Type, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 99: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 117: East Asia Market Attractiveness by Product Type, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 119: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 137: Oceania Market Attractiveness by Product Type, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033
Figure 139: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Product Type, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Product Type, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 157: MEA Market Attractiveness by Product Type, 2023 to 2033
Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033
Figure 159: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
